Product Description
| Product Name |
GS-441524 |
| Expiry Date |
1 Year From The Date Of Manufacture |
| Storage Condition |
Room Temperature |
| CAS Number |
1191237-69-0 |
| Core Function |
Treatment For Cat FIP |
| Dosage Form |
Injection |
| Country of Manufacture |
China |
| Packaging Specs |
6ml/vial, 8ml/vial, 10ml/vial |
| Active Strength |
20mg, 30mg |
GS-441524 is a nucleoside analog compound with targeted antiviral activity against feline coronavirus (FCoV), which is the core pathogenic factor of feline infectious peritonitis (FIP). The antiviral mechanism of GS-441524 is to act on the RNA-dependent RNA polymerase of FCoV, which is the key enzyme for the virus to realize intracellular replication and transcription. As a structural analog of natural nucleosides, GS-441524 is specifically recognized by the viral polymerase and incorporated into the viral RNA synthesis chain during the FCoV replication process. Due to the lack of the functional group required for the continuous extension of the RNA chain, the viral RNA synthesis is terminated after GS-441524 is incorporated, thereby inhibiting the replication and proliferation of FCoV in cat cells and reducing the viral load in the body.
As the primary active metabolite of remdesivir, GS-441524 has a favorable pharmacokinetic profile with a half-life of 24 hours in the mammalian body. This characteristic allows the drug to maintain a stable and effective concentration in the cat's body after a single injection, ensuring a sustained antiviral effect. In the treatment of FIP, GS-441524 can not only directly inhibit viral replication but also alleviate the tissue damage and inflammatory response caused by FCoV infection, thereby improving the clinical symptoms of sick cats and providing a window for the cat's immune system to activate the antiviral response and clear the virus.
About Feline Infectious Peritonitis (FIP)
Feline Infectious Peritonitis (FIP) is a severe, systemic, and highly fatal viral disease unique to domestic cats, caused by the mutation of pathogenic strains of feline coronavirus (FCoV). FCoV is a widely prevalent virus in cat populations, and the infection rate is relatively high in multi-cat breeding environments. The virus is mainly transmitted through the fecal-oral route, and cats can be infected by ingesting contaminated food or water, or by contacting the feces of infected cats and contaminated environmental surfaces.
The occurrence and development of FIP are closely related to the immune status of cats. Cats with a normal and functional immune system can effectively control the replication of FCoV after infection, limiting the virus to the intestinal tract, and thus not developing FIP. However, when the cat's immune function is compromised due to factors such as young age, stress, malnutrition, or concurrent infection with other pathogens, FCoV will mutate in the body. The mutated FCoV can break through the intestinal mucosal barrier, invade the mononuclear phagocyte system, and spread to various tissues and organs throughout the body through the blood circulation, leading to the occurrence of systemic inflammatory response and pathological changes, that is, FIP.
Clinically, FIP is classified into two main types: effusive (wet) FIP and non-effusive (dry) FIP. Effusive FIP is the most common clinical presentation, characterized by the accumulation of a large amount of straw-colored or yellowish turbid exudate in the abdominal cavity, thoracic cavity, or both, leading to abdominal distension, dyspnea, and other obvious symptoms in cats. Non-effusive FIP is relatively less common, characterized by the formation of granulomatous lesions in multiple organs such as the liver, kidney, spleen, and lymph nodes, and the clinical symptoms are insidious and diverse, often including persistent fever, progressive weight loss, and organ dysfunction. In some cases, FIP can involve the eyes and central nervous system, leading to uveitis, ataxia, convulsions, and other symptoms.
The diagnosis of FIP is a challenging process in clinical veterinary medicine due to the non-specificity of its clinical symptoms and laboratory findings. A definitive diagnosis usually requires a combination of epidemiological history, clinical manifestations, blood biochemistry, imaging examinations, and fluid or tissue sample testing. For effusive FIP, the examination of abdominal or thoracic fluid (showing high protein concentration, low nucleated cell count, and the presence of coronavirus antigens or nucleic acids) is an important basis for preliminary diagnosis. At present, there is no approved specific vaccine for the prevention of FIP, and the main preventive strategies focus on reducing the exposure of cats to FCoV, improving the immune function of cats, and maintaining a clean and low-stress feeding environment.
Application and Dosage of GS-441524
GS-441524 is an antiviral preparation that is currently used for the off-label treatment of feline infectious peritonitis in clinical veterinary practice, and its application is targeted at cats that have been clinically diagnosed with FIP and infected with FCoV. The drug is formulated as an injection, which is suitable for subcutaneous or intraperitoneal administration in cats. The dosage of GS-441524 is mainly determined based on the cat's body weight and the clinical type of FIP, and an increased dosage is required for cats with ocular or neurological involvement and recurrent cases to ensure the therapeutic effect.
During the treatment period, the veterinarian will adjust the dosage and treatment course of GS-441524 according to the cat's clinical response, including the improvement of symptoms, the change of viral load, and the physical condition of the cat. It is important to follow the veterinarian's advice for standardized administration to ensure the therapeutic effect and reduce the risk of adverse reactions.
Recommended Dosage Regimen:
- FIP (Wet type): 0.3ml/kg of body weight + 0.1ml residue, injectable administration
- FIP (Dry type): 0.4ml/kg of body weight + 0.1ml residue, injectable administration
- FIP with ocular/neurological involvement: 0.5ml/kg of body weight + 0.1ml residue, injectable administration
- Recurrent FIP cases: 0.6ml/kg of body weight + 0.1ml residue, injectable administration
